BioLineRx (BLRX) Invested Capital (2014 - 2025)

BioLineRx's Invested Capital history runs 12 years deep, the most recent figure standing at $22.7 million for Q4 2025.

• In Q4 2025, Invested Capital rose 26.39% year-over-year to $22.7 million; the TTM figure through Dec 2025 stood at $22.7 million (up 26.39% YoY), while the FY2025 annual figure was $22.7 million, up 26.39% from the prior year.
• Invested Capital was $22.7 million for Q4 2025 at BioLineRx, up from $4.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $22.7 million in Q4 2025 to a low of $802000.0 in Q3 2022.
• Historically, Invested Capital has averaged $5.4 million across 5 years, with a median of $3.3 million in 2021.
• The sharpest annual moves came in 2021 and 2024: Invested Capital plunged 90.1% in 2021, then surged 470.43% in 2024.
• A 5-year view of Invested Capital shows it stood at $2.8 million in 2021, then tumbled by 44.07% to $1.5 million in 2022, then soared by 103.96% to $3.1 million in 2023, then soared by 470.43% to $17.9 million in 2024, then advanced by 26.39% to $22.7 million in 2025.
• The last three Invested Capital figures came in at $22.7 million (Q4 2025), $4.5 million (Q3 2025), and $4.5 million (Q2 2025), per Business Quant data.